Gene therapy targeting a mutation in a nuclear protein has been used to successfully improve health and extend lifespan in a mouse model of Hutchinson-Gilford progeria syndrome.
The inaugural Longevity Therapeutics symposium brought together leading biotech drug developers, academics, investors and pharma companies engaged in creating therapies targeting age-related conditions.
Sessions focused on specific challenges facing these efforts, including discovery, preclinical activities, translational research, clinical development, and regulatory and commercial considerations, and provided a wealth of details about the most recent developments in this space.
Penultimate session of the 2019 Longevity Therapeutics summit. Speakers were Nir Barzila of AECOM, Sree Kant of Life Biosciences, Joan Mannick of resTORbio, Samuel Agus of Biophytis, and Brian Huber of Carolina Longevity Institute.
A panel discussion with Anthony Oliva of Longeveron, Steven Braithwaite of Alkahest, and Ronald Kohanski of the NIA. Session chair John Lewis of Oisín Biotechnologies moderated.
Fourth session of the 2019 Longevity Therapeutics summit. Speakers included Ronald Kohanski of the National Institute on Aging, Morgan Levine of Yale University, Aubrey de Grey of the SENS Foundation, and Kelsey Moody of Ichor Therapeutics.
Third session of the Longevity Therapeutics summit. Speakers were Peter Fedichev of Gero, Kristen Fortney of BioAge, Alex Zhavoronkov of Insilico Medicine, and João Pedro de Magalhães of the University of Liverpool.
Part II of the second session of the Longevity Therapeutics summit. Speakers were Stephen Braithwaite of Alkahest and Mark Bamberger of Stealth BioTherapeutics.
Part I of the second session of the Longevity Therapeutics summit. Speakers included Lorna Harries of the University of Exeter, Marc Ramis-Castelltort of Senolytx, and John Lewis of Oisín Biotechnologies.
Live coverage of the morning session of Longevity Therapeutics 2019. Speakers included Ned David of Unity Biotechnologies, Judith Campisi of the Buck Institute, and a panel discussion with Judy, Aubrey de Grey of the SENS Foundation, and Nir Barzilai of Albert Einstein College of Medicine.
Longevity science presents novel financial, development, regulatory, and clinical challenges to biotechnology/pharmaceutical entrepreneurs. Using one company as an exemplar, this workshop you will explored the fundamentals of launching and growing a successful biotechnology/ pharmaceutical business, with an emphasis on nuances specific to the emerging anti-aging industry.
The centerpiece of the event was a panel discussion among five luminaries of the aging field:
Laura Deming, founder of Longevity Fund and Age1
Simon Melov, professor at the Buck Institute for Research on Aging
Aydin Senkut, founder and managing partner of Felicis Ventures
Kristen Fortney, founder and CEO of BIOAGE
Sonia Arrison (moderator), author of “100 Plus: How the Coming Age of Longevity Will Change Everything”
A first-in-human trial showed that dasatinib+quercetin (DQ), a drug cocktail that targets senescent cells, has beneficial effects in patients with idiopathic pulmonary fibrosis (IPF), a devastating lung disease associated with aging.
RNA sequencing data from human skin cells can be used to predict the donor’s age, bringing us closer to having an accurate, relatively noninvasive biomarker of aging that can be used in longitudinal and population studies.
A new approach using DNA methylation patterns is capable of predicting chronological age more accurately than any previously published model.
Part 2 of a series of articles covering Unity Biotechnology’s inaugural R&D Day, a special presentation to investors and analysts highlighting the company’s recent progress and future plans.
Detailed summaries of Unity Biotechnology’s investor & analyst event, held Dec. 11, 2018.
Fisetin, a natural compound found in berries and other fruits and vegetables, kills senescent cells and extends lifespan in mice.
Bioinformaticians at Mount Sinai analyzed electronic medical record (EMR) data from more than 300,000 patients. Using an AI technique known as deep learning, they could predict a subject’s chronological age from their medical history.
Two widely used antibiotics can kill senescent cells in vitro, illustrating the potential power of drug repurposing approaches to identify approved compounds with novel anti-aging activities.